CO-ANANDA-SCIENTIFIC
8.6.2021 13:02:05 CEST | Business Wire | Press release
ANANDA Scientific Inc. , a biotech pharmaceutical company, and NYU Grossman School of Medicine today announced that the first patient has been enrolled in a clinical trial evaluating Nantheia™ A1002N5S , an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology as a treatment for Post-Traumatic Stress Disorder (PTSD) symptoms and Neurocognitive Impairment in patients with PTSD and with PTSD comorbid with Traumatic Brain Injury (TBI).
“This is an important milestone for ANANDA’s clinical development program, and we look forward to continuing to work with the NYU Grossman School of Medicine. We are impressed by the scientific rigor and professionalism of the NYU team in getting a cutting-edge program in place to test the efficacy of our very promising drug,” said Sohail R. Zaidi, ANANDA’s President . “The initiation of patient enrollment in this study reinforces our commitment to our goal of improving Health and Wellness empowered by cannabinoid science. This is also an important step in our efforts to provide patients with PTSD with potentially improved therapeutic options.”
This trial is being conducted at NYU Grossman School of Medicine, led by Esther Blessing, MD PhD , Assistant Professor of Psychiatry, and Charles R. Marmar, MD, the Lucius N. Littauer Professor and Chair of Psychiatry. Dr. Marmar, leader of the NYU Langone PTSD Research Program, is the primary investigator of several personalized medicine-based clinical trials of innovative treatments for PTSD and its common comorbidities, using cutting-edge biomarker technologies to understand mechanisms underlying treatment effects.
“We are excited to get this important trial underway. Our collaboration with ANANDA Scientific allows us to progress in the development of evidence-based CBD products for this debilitating condition,” said Dr. Marmar.
The Phase II study is an eight week, double-blind, randomized, placebo controlled study with adaptive dose design evaluating the effect of Nantheia™ A1002N5S on PTSD symptoms and neurocognitive function in 120 patients with PTSD, 50% with comorbid mild TBI. (ClinicalTrials.gov Identifier: NCT04550377 )
ABOUT NANTHEIA™ A1002N5S
Nantheia™ A1002N5S is an investigational drug being evaluated for the treatment of PTSD. The drug uses CBD in ANANDA’s propriety delivery technology. Pre-clinical and initial clinical studies show that ANANDA’s Liquid Structure delivery technology (licensed from Lyotropic Delivery Systems (LDS) Ltd. in Jerusalem, Israel) enhances the effectiveness and stability of CBD. Nantheia™ A1002N5S is an oral product with 50 mg CBD per softgel capsule.
ABOUT PTSD
PTSD, a relatively common disorder that may develop following a traumatic event, has a US lifetime prevalence of 1.3–12.2%, with higher rates (12–20%) in individuals exposed to military combat [1, 2] [3]. Disabling symptoms include intrusive memories of the event, avoidance of reminders, negative cognitions and hyperarousal. In addition, PTSD is associated with neurocognitive impairment, which interacts to worsen PTSD symptoms and impair treatment outcomes [4] [5-7] [8, 9]. Traumatic brain injury (TBI), experienced by up to 35% of veterans returning from the OEF/OIF conflicts [10], is often comorbid with PTSD and increases the risk of PTSD by up to 3-fold [11-14]. TBI history is an important factor in PTSD treatment development: even mild TBI can lead to long-term neurocognitive impairment, as well as persistent post concussive symptoms – many of which are common to PTSD symptoms [12, 14-16]. Current pharmacotherapies, largely repurposed from other indications, do not reliably improve PTSD symptoms or associated neurocognitive impairment in PTSD or TBI [17-19]. Novel, targeted medications that treat these overlapping symptoms in a coordinated simultaneous fashion are urgently needed.
ABOUT ANANDA SCIENTIFIC (www.anandascientific.com )
ANANDA is a leading research-focused biotech company pioneering high-caliber clinical studies evaluating therapeutic targets for cannabinoids. The company employs patented delivery technologies to make cannabinoids and other plant derived compounds highly bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium quality nutraceutical and pharmaceutical products. Consistent with its strong research-based data, the company also has a growing pipeline of nutraceutical over-the-counter products. The company has successfully launched these products in the US and the UK, with expansion into additional markets such as the EU, China, Australia and Africa planned for the near future. The company is expanding its research base through multiple sponsored research agreements with universities to diversify its technology portfolio.
REFERENCES
- Kessler, R.C., et al., Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 2005. 62 (6): p. 593-602.
- Hoge, C.W., et al., Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med, 2004. 351 (1): p. 13-22.
- Shalev, A., I. Liberzon, and C. Marmar, Post-Traumatic Stress Disorder. N Engl J Med, 2017. 376 (25): p. 2459-2469.
- Hayes, J.P., M.B. Vanelzakker, and L.M. Shin, Emotion and cognition interactions in PTSD: a review of neurocognitive and neuroimaging studies. Front Integr Neurosci, 2012. 6 : p. 89.
- Haaland, K.Y., et al., Neurocognitive Correlates of Successful Treatment of PTSD in Female Veterans. J Int Neuropsychol Soc, 2016. 22 (6): p. 643-51.
- Aupperle, R.L., et al., Dorsolateral prefrontal cortex activation during emotional anticipation and neuropsychological performance in posttraumatic stress disorder. Arch Gen Psychiatry, 2012. 69 (4): p. 360-71.
- Aupperle, R.L., et al., Executive function and PTSD: disengaging from trauma. Neuropharmacology, 2012. 62 (2): p. 686-94.
- Nijdam, M.J., et al., Neurocognitive functioning over the course of trauma-focused psychotherapy for PTSD: Changes in verbal memory and executive functioning. Br J Clin Psychol, 2018.
- Morey, R.A., et al., Neural systems for executive and emotional processing are modulated by symptoms of posttraumatic stress disorder in Iraq War veterans. Psychiatry Res, 2008. 162 (1): p. 59-72.
- Rigg, J.L. and S.R. Mooney, Concussions and the military: issues specific to service members. PM R, 2011. 3 (10 Suppl 2): p. S380-6.
- Langlois, J.A., W. Rutland-Brown, and M.M. Wald, The epidemiology and impact of traumatic brain injury: a brief overview. J Head Trauma Rehabil, 2006. 21 (5): p. 375-8.
- Stein, M.B. and T.W. McAllister, Exploring the convergence of posttraumatic stress disorder and mild traumatic brain injury. Am J Psychiatry, 2009. 166 (7): p. 768-76.
- Tanev, K.S., et al., PTSD and TBI co-morbidity: scope, clinical presentation and treatment options. Brain Inj, 2014. 28 (3): p. 261-70.
- Kaplan, G.B., et al., Pathophysiological Bases of Comorbidity: Traumatic Brain Injury and Post-Traumatic Stress Disorder. J Neurotrauma, 2018. 35 (2): p. 210-225.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005132/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Infobip Expands Relationship With Anthropic With Verified Claude Connector for Global Messaging17.11.2026 10:00:00 CET | Press release
New integration enables Claude users to send and track messages across SMS, RCS, MMS and Viber through Infobip. Global AI-first cloud communications platform Infobip has expanded its collaboration with Anthropic with the launch of the Infobip Message connector in the Claude Marketplace. The Anthropic-verified connector enables developers, enterprises and builders using Claude to add global messaging capabilities to AI agents without building separate integrations for individual communication channels. The integration connects Claude with Infobip’s global communications infrastructure, enabling AI agents to send messages across SMS, RCS, MMS and Viber through a single connector. Using Infobip’s send and check status tools, agents can trigger outbound messages and track their delivery status, allowing them to incorporate real-world communication into automated workflows. For businesses building agentic AI applications, the connector can support use cases such as order confirmations, deli
Luminor Partners With Plumery to Accelerate Delivery of Digital Banking Solutions17.11.2026 09:55:00 CET | Press release
Luminor has partnered with financial technology company Plumery, using its headless digital platform to accelerate the delivery of selected digital banking solutions across Estonia, Latvia and Lithuania. Plumery was selected because its technology and approach align well with Luminor’s strategy. The cooperation forms part of Luminor’s broader work to modernise its technology, simplify its products and strengthen its digital channels. Under the partnership, Luminor uses Plumery’s headless, API-first architecture to design and deliver digital banking experiences in combination with the bank’s own applications, customer journeys and integrations. This allows Luminor to develop and introduce new functionality more efficiently, while retaining control over how its digital services are designed and integrated. Luminor Bloom, hosted on Luminor’s new cloud-based banking platform, is the first solution delivered through the partnership. Plumery provides the digital banking interface used for Lu
Oasis Networks Selects PacketLight for Burstable Wavelength Services17.11.2026 09:35:00 CET | Press release
PacketLight Networks, a provider of DWDM and OTN optical transport solutions, today announced that Oasis Networks has selected its 800G transport and OLS optical amplification platforms to support the development of burstable wavelength services in Portugal. PacketLight’s open transport architecture supports Oasis’ plans to allocate optical capacity through software as customer requirements change. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117351242/en/ PacketLight’s 800G DWDM transport and OLS optical amplification support Oasis Networks’ Lisbon–Sines connection and the development of burstable wavelength services. The connection between Lisbon and Sines is now in place, with the Sines endpoint at Start Campus. A proof of concept on Oasis’ operational network demonstrated software-controlled optical path establishment and reconfiguration. PacketLight has also completed the design for future site interconnects around
Abu Dhabi International Boat Show Opens This Week With World Premieres and Record Participation17.11.2026 09:27:00 CET | Press release
Held under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region, the Abu Dhabi International Boat Show (ADIBS) returns from 19 to 22 November 2026 at ADNEC Marina Hall for its eighth and largest edition yet, bringing together 1,210 exhibitors and brands from 57 countries, a 13% increase on 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116669938/en/ ADNEC Marina Hall - ADNEC Group, Abu Dhabi – United Arab Emirates (Photo: AETOSWire) Organised by ADNEC Group under the theme “Life on and Beyond the Water”, the show spans more than 96,000 square metres and will feature 168 boats on display in the marina. Additionally, luxury yachts, houseboats, leisure boats and marine sports equipment will be launched for the first time in the region. “This year’s edition is set to be the largest in the Show’s history, with strong growth across key performance indicators reflectin
Lakestar and Rochefort Asset Management Co-Lead Series A for Tiberius Aerospace at over $1 Billion Valuation17.11.2026 09:00:00 CET | Press release
Financing will accelerate production of long-range precision munitions and expand allied sovereign manufacturing capacity. Lakestar, a European technology investment firm and Rochefort Asset Management (Rochefort), a U.S. national security-focused investment firm licensed under the U.S. Department of War's Office of Strategic Capital (OSC) and the Small Business Administration (SBA), today jointly announced that they have co-led an $85 million Series A financing round for defense technology company Tiberius Aerospace, Inc. (Tiberius). The investment values Tiberius at more than $1 billion on a post-money basis making it the latest defense technology unicorn. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117903633/en/ Tiberius Aerospace becomes a defense tech unicorn The round attracted new investors including Dream Ventures and Aero X Ventures, alongside other institutional investors, with participation from existing inv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
